Foundation board hears BioBridge Global’s role in the future of medicine
Geoff Kindt, General Manager of GenCure biomanufacturing, simplified a complex concept for members of The Blood & Tissue Center Foundation Board of Directors on Monday – advanced therapies.
Advanced therapies, he explained, refers to innovative medical treatments, including cell therapy, gene therapy and more. They offer new ways to treat complicated and previously untreatable conditions.
Kindt, along with CEO Marty Landon, talked about advanced therapies and their role in the future of BioBridge Global. The meeting was held at the VelocityTX biotech incubator complex, where GenCure is located.
“The beauty of what we do,” Kindt said, “is hearing the outcome.”
He mentioned rare diseases that have found cures through treatment, as well as the development of those therapies in cleanrooms like those at GenCure.
While he spoke, scientist Roger Palacios began the grueling process of donning cleanroom attire for all to see. This included necessary layers that can take up to a half-hour from start to finish.
“The critical piece is you do not contaminate your product,” Kindt said. “There cannot be any bioburden. There cannot be particles.”
Kindt explained that GenCure works in multiple phases of clinical development, helping researchers move new cures through clinical trials and into new therapies available to patients.
Landon thanked board members for their contributions to the organization, saying they will help pave the way for the next 50 years. He noted that GenCure is helping save lives through job stability and multiple projects with researchers.
Advanced therapies are becoming part of the organization’s focus. These join blood and tissue operations, and are considered the future of medicine.
“Nothing is changing,” Landon said. “We have a history of innovation, evolving from care, to cures. Why? Because that’s where the practice of medicine is going. And so, we want to move right along with that.”
Board members also toured the facility with Dr. Mari Salmi, Senior Director, Process Development & Cell Testing, and Dr. Rogelio Zamilpa, Senior Director of Manufacturing Sciences & Technology.
